Population-based study evaluates survival outcomes of primary uveal diffuse large B-cell lymphoma, suggesting implications for management.
Purpose Primary involvement of the uveal tract by diffuse large B-cell lymphoma is exceedingly rare and poorly characterized. Most reported ocular lymphomas in this location are indolent mucosa-associated lymphoid tissue lymphomas with favourable outcomes. We aimed to evaluate the epidemiologic and clinical features of primary uveal diffuse large B-cell lymphoma using a large population-based dataset. Material and methods We performed a retrospective analysis of cases recorded between 2000 and 2022 in the Surveillance, Epidemiology, and End Results (SEER) database. Eligible patients had histologically confirmed diffuse large B-cell lymphoma with primary localization in the choroid (C69.3) or ciliary body/iris (C69.4). Localized primary uveal diffuse large B-cell lymphoma was defined as Ann Arbor stage I disease without systemic involvement. Survival outcomes were analysed using Kaplan–Meier estimates and Cox univariate models. Results Among 134,366 diffuse large B-cell lymphoma cases, 51 involved the uveal tract (0.038 %), with 42 (82.4 %) classified as localized primary uveal diffuse large B-cell lymphoma. Median age was 65 years; most patients were Caucasian. The 5-year overall survival and cancer-specific survival rates were 45.5 % and 58.4 %, respectively. For patients with localized diseases, 5-year cancer-specific survival rate was 59.4 %, with a survival plateau beyond 6 years. No significant associations were found between overall- or cancer-specific survival and clinical or treatment variables, including radiotherapy or chemotherapy. Conclusions Primary uveal diffuse large B-cell lymphoma is an ultra-rare and aggressive malignancy, distinct from uveal mucosa-associated lymphoid tissue lymphoma. While outcomes are poorer, a subset of patients with localized disease may achieve long-term remission. Radiotherapy may be a treatment alternative for selected patients, though optimal management remains undefined. Further prospective studies are warranted.
No takes yet. Share an insight, caveat, or question.
Loap et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: